Francesco Nuzzo

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 478 citations · Full text

The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy

Francesco Perrone, Claudio Jommi, Massimo Di Maïo et al. · Annals of Oncology · 2016 · 149 citations · Full text

Family Medicine, Health Policy, Health Economics +12

Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer

Francesca Collina, Maurizio Di Bonito, Valeria Li Bergolis et al. · BioMed Research International · 2015 · 105 citations · Full text

Breast Oncology, Oncology, Medicine +13

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7